Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer
Open Access
- 23 February 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Molecular Cancer
- Vol. 20 (1), 1-6
- https://doi.org/10.1186/s12943-021-01331-9
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China (81872499, 81772476, 81972898, 81972556)
- Postdoctoral Research Foundation of China (2020M683122)
- Science and Technology Program of Guangzhou (2019A1515011090)
- Medical Scientific Research Foundation of Guangdong Province (C2018062)
- Outstanding Young Talents Program of Sun Yat-sen University Cancer Center (16zxyc04)
This publication has 8 references indexed in Scilit:
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung CancerCancer Discovery, 2017
- Clonal neoantigens and immune response: a balancing actNature Reviews Clinical Oncology, 2016
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockadeScience, 2016
- Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencingScience, 2014
- Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastomaScience, 2014
- MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinomaOral Oncology, 2013
- Cancer Genome LandscapesScience, 2013
- Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic LeukemiaCell, 2013